Skip to Main Content

The second-highest executive at Mylan (MYL) is the target of a widening civil investigation being conducted by dozens of states into allegations that numerous generic drug makers conspired to fix prices.

Attorneys general from 45 states want to add Rajiv Malik, the Mylan president and an executive director, to a lawsuit that was initially filed late last year. The original suit alleged six generic drug makers, including Mylan, colluded to set prices for two medicines. But an amended lawsuit — if approved by a federal court — would add another dozen companies and now cites 15 different drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.